It works by switching off nociceptors in the peripheral nervous system, and therefore preventing pain signals getting to the brain. This represents a potential new breakthrough in a world which has ...

The lived experience of severe pain, understandably, can lead to a process of catastrophizing, which is a cognitive distortion where patients assume the worst possible outcome in any situation where ...

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Accurate pain reporting in sickle cell disease is critical to effective pain assessment and management, but accuracy depends on patient comprehension of forms.